Donald L Gilbert1, J Robert Batterson, Gopalan Sethuraman, Floyd R Sallee. 1. Department of Neurology, Cincinnati Children's Hospital Medical Center, Division of Developmental and Behavioral Sciences. Children's Mercy Hospital, Kansas City, KS, USA. d.gilbert@cchmc.org
Abstract
OBJECTIVE: To compare the tic suppression, electrocardiogram (ECG) changes, weight gain, and side effect profiles of pimozide versus risperidone in children and adolescents with tic disorders. METHOD: This was a randomized, double-blind, crossover (evaluable patient analysis) study. Nineteen children aged 7 to 17 years with Tourette's or chronic motor tic disorder were randomized to 4 weeks of treatment with pimozide or risperidone, followed by the alternate treatment after a 2-week placebo washout. The primary efficacy outcome measure was change in tic severity assessed by the Yale Global Tic Severity Scale (YGTSS). ECG results, weight gain, and side effects were also compared. RESULTS: Compared to pimozide treatment, risperidone treatment was associated with significantly lower tic severity scores (YGTSS: baseline 43.3 +/- 17.5, pimozide 34.2 +/- 14.2, risperidone 25.2 +/- 13.6; p =.05). Weight gain during the 4-week treatment periods was greater for risperidone (mean 1.9 kg) than pimozide (1.0 kg). No patient suffered a serious adverse event, but 6 of 19 subjects failed to complete the protocol. Neither medication was associated with ECG changes. CONCLUSIONS: In this study, risperidone appeared superior to pimozide for tic suppression but was associated with greater weight gain.
RCT Entities:
OBJECTIVE: To compare the tic suppression, electrocardiogram (ECG) changes, weight gain, and side effect profiles of pimozide versus risperidone in children and adolescents with tic disorders. METHOD: This was a randomized, double-blind, crossover (evaluable patient analysis) study. Nineteen children aged 7 to 17 years with Tourette's or chronic motor tic disorder were randomized to 4 weeks of treatment with pimozide or risperidone, followed by the alternate treatment after a 2-week placebo washout. The primary efficacy outcome measure was change in tic severity assessed by the Yale Global Tic Severity Scale (YGTSS). ECG results, weight gain, and side effects were also compared. RESULTS: Compared to pimozide treatment, risperidone treatment was associated with significantly lower tic severity scores (YGTSS: baseline 43.3 +/- 17.5, pimozide 34.2 +/- 14.2, risperidone 25.2 +/- 13.6; p =.05). Weight gain during the 4-week treatment periods was greater for risperidone (mean 1.9 kg) than pimozide (1.0 kg). No patient suffered a serious adverse event, but 6 of 19 subjects failed to complete the protocol. Neither medication was associated with ECG changes. CONCLUSIONS: In this study, risperidone appeared superior to pimozide for tic suppression but was associated with greater weight gain.
Authors: Constadina Panagiotopoulos; Rebecca Ronsley; Dean Elbe; Jana Davidson; Derryck H Smith Journal: J Can Acad Child Adolesc Psychiatry Date: 2010-05
Authors: John Piacentini; Douglas W Woods; Lawrence Scahill; Sabine Wilhelm; Alan L Peterson; Susanna Chang; Golda S Ginsburg; Thilo Deckersbach; James Dziura; Sue Levi-Pearl; John T Walkup Journal: JAMA Date: 2010-05-19 Impact factor: 56.272
Authors: Hannah Weisman; Imraan A Qureshi; James F Leckman; Lawrence Scahill; Michael H Bloch Journal: Neurosci Biobehav Rev Date: 2012-10-23 Impact factor: 8.989
Authors: Matt W Specht; Douglas W Woods; John Piacentini; Lawrence Scahill; Sabine Wilhelm; Alan L Peterson; Susanna Chang; Hayden Kepley; Thilo Deckersbach; Christopher Flessner; Brian A Buzzella; Joseph F McGuire; Sue Levi-Pearl; John T Walkup Journal: J Dev Phys Disabil Date: 2011-02
Authors: Rafael Garcia-Lopez; Emilio Perea-Milla; Cesar Ruiz Garcia; Francisco Rivas-Ruiz; Julio Romero-Gonzalez; Jose L Moreno; Vicente Faus; Guadalupe del Castillo Aguas; Juan C Ramos Diaz Journal: Trials Date: 2009-03-10 Impact factor: 2.279